Clinical trialPhase 2Unknown
A Study of Administering FOLFIRINOX Before Surgery For Potentially Curable Pancreatic Cancer
A Study of Preoperative FOLFIRINOX For Potentially Curable Pancreatic Cancer
- Outcome
- Outcome unknown
- Phase
- Phase 2
- Status
- Unknown
- Study type
- Interventional
- Start
- 3 July 2017
- Expected end
- May 2018
- Enrollment
- 20 participants
- Sites
- 1
- Primary outcomes
- Time to Progression (TTP).
- Sponsor
- Other
- Results posted
- No
- Last update
- 29 August 2017
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 28
- BackgroundPreoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Panc… DOI 10.1001/jamasurg.2016.1137↗
- BackgroundNeoadjuvant therapy for non-metastatic pancreatic ductal adenocarcinoma. DOI 10.1053/j.seminoncol.2014.12.008↗
- BackgroundNeoadjuvant FOLFIRINOX application in borderline resectable pancreatic adenocarcinoma: a retrospective cohort study. DOI 10.1097/md.0000000000000198↗
- BackgroundPostoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. DOI 10.1097/sla.0000000000000378↗
- BackgroundA single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancr… DOI 10.1097/sla.0000000000000251↗
- BackgroundProjecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the Un… DOI 10.1158/0008-5472.can-14-0155↗
- BackgroundThe impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy f… DOI 10.1245/s10434-014-3722-6↗
- BackgroundAggressive surgery for borderline resectable pancreatic cancer: evaluation of National Comprehensive Cancer Network gui… DOI 10.1097/mpa.0b013e31827b2d7c↗
- BackgroundBorderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. DOI 10.1245/s10434-013-2886-9↗
- BackgroundPancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. DOI 10.6004/jnccn.2012.0073↗
- BackgroundManagement of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and … DOI 10.1016/j.jamcollsurg.2011.09.022↗
- BackgroundAdjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic canc… DOI 10.1186/1471-2407-11-346↗
- BackgroundSurvival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. DOI 10.1245/s10434-011-1900-3↗
- BackgroundFOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. DOI 10.1056/nejmoa1011923↗
- BackgroundValidation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma. DOI 10.1111/j.1477-2574.2009.00110.x↗
- BackgroundLong-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. DOI 10.1245/s10434-008-0295-2↗
- BackgroundUtilization and determinants of adjuvant therapy among older patients who receive curative surgery for pancreatic cance… DOI 10.1097/mpa.0b013e318187eb3f↗
- BackgroundPreoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. DOI 10.1200/jco.2007.15.8634↗
- BackgroundPreoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of th… DOI 10.1200/jco.2007.15.8642↗
- BackgroundLong-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or obser… DOI 10.1097/sla.0b013e318156eef3↗
- BackgroundImpact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcino… DOI 10.1097/01.sla.0000259391.84304.2b↗
- BackgroundAdjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic ca… DOI 10.1001/jama.297.3.267↗
- BackgroundBorderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. DOI 10.1245/aso.2006.08.011↗
- BackgroundCancer statistics, 2006. DOI 10.3322/canjclin.56.2.106↗
- BackgroundGemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreati… DOI 10.1200/jco.2005.06.023↗
- BackgroundAdjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: p… DOI 10.1097/00000658-199912000-00006↗
- BackgroundResection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. DOI 10.1097/00000658-199302000-00008↗
- BackgroundPancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. DOI 10.1001/archsurg.1985.01390320023003↗